Morpholino

MO6-fgfr2

ID
ZDB-MRPHLNO-130911-3
Name
MO6-fgfr2
Previous Names
  • fgfr2b exon 7/intron 7 splice-blocking MO1 (1)
Target
Sequence
5' - CCTGCTTTTTTACCTGGTATGACAA - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
Splice-blocking MO.
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO6-fgfr2
Phenotype
Phenotype resulting from MO6-fgfr2
Phenotype of all Fish created by or utilizing MO6-fgfr2
Phenotype Fish Conditions Figures
forebrain oligodendrocyte plp1a expression increased amount, abnormal WT + MO6-fgfr2 standard conditions Fig. 4 from Miyake et al., 2023
midbrain development disrupted, abnormal WT + MO6-fgfr2 standard conditions Fig. 5 with imageFig. 6 with image from Miyake et al., 2013
telencephalon gad1b expression decreased amount, abnormal WT + MO6-fgfr2 standard conditions Fig. 3 from Miyake et al., 2023
forebrain astrocyte glula expression decreased amount, abnormal WT + MO6-fgfr2 standard conditions Fig. 4 from Miyake et al., 2023
diencephalon gad1b expression decreased amount, abnormal WT + MO6-fgfr2 standard conditions Fig. 3 from Miyake et al., 2023
telencephalon slc17a6a expression decreased amount, abnormal WT + MO6-fgfr2 standard conditions Fig. 3 from Miyake et al., 2023
cell proliferation in midbrain decreased occurrence, abnormal WT + MO6-fgfr2 standard conditions Fig. 3 with image from Miyake et al., 2013
forebrain astrocyte development decreased process quality, abnormal WT + MO6-fgfr2 standard conditions Fig. 4 from Miyake et al., 2023
optic tectum physical object quality, abnormal WT + MO6-fgfr2 standard conditions Fig. 6 with image from Miyake et al., 2013
forebrain neurogenesis decreased occurrence, abnormal WT + MO6-fgfr2 standard conditions Fig. 3 from Miyake et al., 2023
diencephalon slc17a6a expression decreased amount, abnormal WT + MO6-fgfr2 standard conditions Fig. 3 from Miyake et al., 2023
forebrain oligodendrocyte development increased process quality, abnormal WT + MO6-fgfr2 standard conditions Fig. 4 from Miyake et al., 2023
Citations